Dermata pivots to OTC dermatology, withdraws XYNGARI IND, plans acne kit launch mid-2026

Dermata Therapeutics, Inc.

Strategic shift to prioritize OTC dermatology products sold directly to consumers.
Initial focus on once-weekly acne kit using approved monograph active ingredient and Spongilla technology.
Plans to launch the acne kit in mid-2026 with additional OTC products to follow.
Withdrew its investigational new drug application for XYNGARI with the FDA.
Aims to accelerate commercialization path and reduce regulatory burdens.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.